IDT Expands CRISPR Toolkit to Support Translational Gene Editing

Integrated DNA Technologies (IDT), a major supplier of synthetic nucleic acids, has broadened its CRISPR reagent portfolio with tools aimed at translational research, including high-purity guide RNAs (gRNAs) and off-target detection services. The launch reflects a broader push in the field to translate genome-editing discoveries into clinically viable therapies.

Among the applications for the expanded suite of tools is a personalized gene-editing therapy recently developed for KJ Muldoon, an infant with CPS1 deficiency, a rare metabolic disorder. The therapy, delivered under a compressed development timeline, combined CRISPR-based editing with custom manufacturing from IDT and Aldevron. IDT provided the gRNAs and analytical services used to assess off-target activity prior to treatment.

The company’s newly available gRNAs are chemically synthesized and offered with a variety of chemical modifications, including 2’ Fluoro and 2’ O-Methyl groups to enhance stability and target specificity. These reagents are available in multiple yield options and purification grades, including high-performance liquid chromatography, which is often required for ex vivo and in vivo translational models.

As CRISPR-based approaches inch closer to regulatory approval, off-target analysis remains a key safety concern. To address this, IDT has launched a service called UNCOVERseq, which builds on the GUIDE-seq method to map potential off-target edits in the genome. The service is designed to help researchers identify unintended edits at an early stage in therapeutic development. It complements IDT’s rhAmpSeq platform, which is used to confirm off-target activity with high sensitivity.

The customized safety assays developed in support of baby KJ’s therapy played a role in validating UNCOVERseq, according to the company. While individual cases like this remain rare, they highlight the practical challenges of moving from bench to bedside in genome editing.